At the same time, however, this failure could be the impetus for a "we don't know what we don't know" type of approach. This strategy, consisting of searching for molecular/genome signatures that distinguish, for example, one disease from another, will allow us to gain information that can be used in turn to enhance protein networks and mathematical models; these networks and models will enable us to unravel functionally meaningful interactions within complex biological systems. This in silico analysis may help to investigate, for example, the inner workings of a given drug in a specific pathological context. In essence, this approach may aid us in solving a "we do know what we don't know" type of question, such as "Why correcting high glucose levels is so beneficial in DM but not so much so in HF?" or "Is a given drug effective by modifying the same or different targets in different pathological contexts"? Science author instructions page. Jun et al. 4 in the failing heart." Accordingly, the long-term ablation of NHE1 activity enhances the myocyte redox potential and mitigates high-fat diet-induced myocardial stress and fatty liver disease, leading to better-preserved insulin sensitivity, while potentially altering both cardiac and systemic metabolic substrate handling in mice (6) .
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In aggregate, the study by Iborra-Egea et al. (2) Some mechanisms that explain the benefits afforded by empagliflozin to patients with heart failure and reduced ejection fraction, and cardiac effects already attributed to the inhibition of NHE1 activity. The dotted line represents additional yet to be verified salutary actions.
TGF ¼ transforming growth factor. 
Empagliflozin and HFrEF
Thanks to the present study (2) 
